Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
Cell Differentiation
/ drug effects
Chikungunya virus
/ drug effects
Cytokines
/ classification
Dendritic Cells
/ drug effects
Ebolavirus
/ drug effects
Gene Expression Profiling
Gene Expression Regulation
/ drug effects
Hepatitis E virus
/ drug effects
Humans
Immunity, Innate
/ drug effects
Immunologic Factors
/ pharmacology
Macrophages
/ drug effects
Organ Specificity
Picornaviridae
/ drug effects
Primary Cell Culture
SARS-CoV-2
Signal Transduction
Triterpenes
/ pharmacology
Zika Virus
/ drug effects
RNA viruses
antiviral
cytokines
eIF4A
energy metabolism
immune modulation
rocaglate
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
10
02
2020
revised:
31
03
2020
accepted:
16
04
2020
pubmed:
7
5
2020
medline:
1
7
2020
entrez:
7
5
2020
Statut:
ppublish
Résumé
Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new antiviral drug candidate silvestrol effectively inhibited replication of Corona-, Ebola-, Zika-, Picorna-, Hepatis E and Chikungunya viruses. Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens. In the present study, silvestrol down-regulated several pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, CCL2, CCL18) and increased TNF-α during differentiation and activation of M1-macrophages, suggesting that the effects of silvestrol might cancel each other out. However, silvestrol amplified the anti-inflammatory potential of M2-macrophages by increasing expression of anti-inflammatory surface markers CD206, TREM2 and reducing release of pro-inflammatory IL-8 and CCL2. The differentiation of dendritic cells in the presence of silvestrol is characterized by down-regulation of several surface markers and cytokines indicating that differentiation is impaired by silvestrol. In conclusion, silvestrol influences the inflammatory status of immune cells depending on the cell type and activation status.
Identifiants
pubmed: 32374474
doi: 10.1111/jcmm.15360
pmc: PMC7267175
doi:
Substances chimiques
Antiviral Agents
0
Cytokines
0
Immunologic Factors
0
Triterpenes
0
silvestrol
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6988-6999Subventions
Organisme : LOEWE TBG
Pays : International
Organisme : LOEWE DRUID
Pays : International
Organisme : LOEWE TMP
Pays : International
Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Viruses. 2018 Oct 30;10(11):
pubmed: 30380742
N Engl J Med. 2015 Feb 5;372(6):584-7
pubmed: 25539446
Cytokine. 2018 Sep;109:52-56
pubmed: 29402725
Semin Cell Dev Biol. 2008 Aug;19(4):351-9
pubmed: 18620071
Eur J Pharmacol. 2015 Sep 15;763(Pt B):169-77
pubmed: 25981299
BMC Cancer. 2016 Jan 13;16:17
pubmed: 26762417
J Cell Mol Med. 2020 Jun;24(12):6988-6999
pubmed: 32374474
Blood. 2009 May 7;113(19):4656-66
pubmed: 19190247
PLoS One. 2013 Sep 26;8(9):e76136
pubmed: 24086701
Cytokine Growth Factor Rev. 2016 Oct;31:1-15
pubmed: 27185365
Antiviral Res. 2017 Jan;137:76-81
pubmed: 27864075
ACS Chem Biol. 2013 Jul 19;8(7):1519-27
pubmed: 23614532
Kidney Blood Press Res. 2000;23(3-5):173-4
pubmed: 11031712
Front Immunol. 2018 Feb 19;9:270
pubmed: 29520272
Molecules. 2015 Jan 29;20(2):2229-71
pubmed: 25642836
J Clin Invest. 2008 Jul;118(7):2651-60
pubmed: 18551192
Sci Rep. 2017 Jan 11;7:39566
pubmed: 28074916
J Immunol. 2004 Feb 15;172(4):2307-15
pubmed: 14764699
Curr Hepat Rep. 2013;12(4):200-213
pubmed: 32214912
Viruses. 2018 Jun 02;10(6):
pubmed: 29865243
Trends Pharmacol Sci. 2012 Feb;33(2):89-99
pubmed: 22196854
Nat Immunol. 2000 Dec;1(6):510-4
pubmed: 11101873
J Exp Med. 2011 Aug 29;208(9):1799-807
pubmed: 21859846
J Immunol. 2001 Apr 1;166(7):4312-8
pubmed: 11254683
Immunobiology. 2009;214(7):554-61
pubmed: 19162368
Int J Mol Sci. 2018 Jun 19;19(6):
pubmed: 29921749
Eur J Pharmacol. 2018 Aug 15;833:328-338
pubmed: 29920284
Front Immunol. 2014 Nov 26;5:603
pubmed: 25505468
Front Immunol. 2015 Oct 27;6:549
pubmed: 26579124
Oncogene. 2015 Jul;34(28):3728-36
pubmed: 25241892
J Immunol. 2014 Nov 1;193(9):4335-43
pubmed: 25246496
Oncotarget. 2015 Feb 20;6(5):2693-708
pubmed: 25393910
Biochem Biophys Rep. 2015 Nov 05;4:397-404
pubmed: 29124230
Nature. 2014 Sep 4;513(7516):65-70
pubmed: 25079319
Br J Pharmacol. 2012 Mar;165(5):1348-60
pubmed: 21726210
Antimicrob Agents Chemother. 1998 Jun;42(6):1499-502
pubmed: 9624502
J Cytol Mol Biol. 2014 Jan 10;1(1):
pubmed: 24672807
Blood. 2009 Jan 22;113(4):887-92
pubmed: 18849484
Nat Med. 2018 Dec;24(12):1877-1886
pubmed: 30374200
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8357-62
pubmed: 18550825
Infect Agent Cancer. 2017 Mar 23;12:18
pubmed: 28344640
Arthritis Rheum. 2009 May;60(5):1451-62
pubmed: 19404962
Chest. 1994 Oct;106(4):1116-23
pubmed: 7924482
Viruses. 2018 Mar 27;10(4):
pubmed: 29584632
Eur Respir J. 1995 Sep;8(9):1451-7
pubmed: 8575568
Antiviral Res. 2018 Feb;150:123-129
pubmed: 29258862
Blood. 2013 Jun 20;121(25):5034-44
pubmed: 23482932
Anticancer Res. 2007 Jul-Aug;27(4B):2175-83
pubmed: 17695501
J Leukoc Biol. 2005 May;77(5):739-47
pubmed: 15713699
Immunology. 2013 Sep;140(1):22-30
pubmed: 23621371
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):528-33
pubmed: 21187426